The global genome editing market is rapidly increasing due to the increased government funding for genomics technology, rise in the production of genetically modified crops and technological advancements these all factors are driving the growth of this market.
Recent developments across genome editing technologies have resulted in the creation of next generation nucleases that have higher levels of accuracy when correcting genetic mutations and defects. The classes under the genome editing technologies are the 4 broad families of nucleases: ZFNs, TALENs, CRISPR/Cas9, and Meganucleases.
Gene editing technologies have an impact across multiple applications areas including plant and animal genetic engineering. However, the area of most disruption is across human cell line engineering, which enables the development of next generation’s therapies and drugs. However, the agricultural industry has seen more success with gene editing techniques largely due to the less stringent regulatory environment.
This market research report categorizes the genome editing market into the following segments:
• Antisense Technology
• Other Technologies
• Cell Line Engineering
• Animal Genetic Engineering
• Plant Genetic Engineering
• Other Applications
By End User
• Biotechnology and Pharmaceutical Companies
• Government and Academic Research Institutes
• Other Research Organizations
By Geographical Region
• North America
• Rest of the World
1.1 KEY TAKE AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 MARKET SHARE
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
2 Research Methodology
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.2 Primary Research
220.127.116.11 Key Data From Primary Sources
18.104.22.168 Key Industry Insights
2.3 Market Size Estimation Methodology
2.3.1 Market Data Validation and Triangulation
2.3.2 Assumptions for the Study
3 Executive Summary
4 Premium Insights
4.1 Genome Editing: Market Overview
4.2 Geographic Analysis: Genome Editing Market, By Application (2016)
4.3 Market Size, By Technology, 2016 vs 2021
4.4 Market Size, By Application, 2016 vs 2021
4.5 Market Size, By End User, 2016 vs 2021
4.6 Geographical Snapshot of the Genome Editing Market
5 Market Overview
5.2 Market Dynamics
22.214.171.124 Rising Government Funding and Growth in the Number of Genomics Projects
126.96.36.199 High Prevalence Rate of Infectious Diseases and Cancer Among Patients
188.8.131.52 Technological Advancements
184.108.40.206 Increase in Demand for Synthetic Genes
220.127.116.11 Rise in Production of Genetically Modified Crops
18.104.22.168 Increasing Awareness About Genomics
22.214.171.124 New Product Launches By Industry Players
126.96.36.199 High Cost of Genomic Equipment
188.8.131.52 Adverse Public Perception Related to Genetic Research
184.108.40.206 Use of Genome Editing in Specialized/Personalized Medicine
220.127.116.11 Emerging Markets in Developing Countries
18.104.22.168 Off-Target Effect of CRISPR
22.214.171.124 Shortage of Trained Professionals
6 Global Genome Editing/Engineering Market, By Technology
6.6 Other Technologies
7 Global Genome Editing/Genome Engineering Market, By Application
7.2 Cell Line Engineering
7.3 Animal Genetic Engineering
7.4 Plant Genetic Engineering
7.5 Other Applications
8 Global Genome Editing/Engineering Market, By End User
8.2 Biotechnology & Pharmaceutical Companies
8.3 Academic & Government Research Institutes
8.4 Contract Research Organizations
9 Genome Editing/Genome Engineering Market, By Region
9.2 North America
126.96.36.199 Development of Gene Therapy in the U.S.
188.8.131.52 Increasing Use of Gm Crops
184.108.40.206 Prevalence of Alzheimer’s Disease and Other Dementias in the United States
220.127.116.11 Genome Editing Conferences in the U.S.
18.104.22.168 Rising Availability of Research Grants and Funding
22.214.171.124 Genome Editing Standards Workshop in the U.S.
126.96.36.199 Increasing Prevalence of Cancer
188.8.131.52 Strategic Developments in the U.S. Market
184.108.40.206 Availability of Research Funding in Canada
220.127.116.11 Rising Incidence of Cancer
18.104.22.168 Gapp to Intensify Genomic R&D
9.3.1 Conferences and Meetings in Europe
22.214.171.124 Increased Funds, and Grants By Government Bodies
126.96.36.199 100,000 Genomes Project in U.K.
188.8.131.52 Availability of Funding for Life Science Research
184.108.40.206 Conferences/Meetings/ Symposiums/Workshops in Germany
220.127.116.11 Spain’s Focus on Research
18.104.22.168 Growth in the Italian Biotech and Pharma Sectors
22.214.171.124 Growing Research Investments in Sweden & Denmark
126.96.36.199 High Intensity of R&D Activities in China
188.8.131.52 Growing Focus of Global Companies on China
184.108.40.206 Involvement of Industry Players in the Japanese Market: Significant Developments
220.127.116.11 Conferences and Symposiums on Genetic Engineering in Japan
18.104.22.168 Focus on Cancer Research and Treatment
22.214.171.124 Emergence of Local Players in India
126.96.36.199 Growth of the Pharmaceutical Industry in India
188.8.131.52 Development of Bio-Clusters to Boost India’s Biotechnology Industry
184.108.40.206 Australia: Availability of Financial Support for Research
220.127.116.11 Genome Asia 100k Initiative
18.104.22.168 Crop Research Initiatives in Asia
9.5.1 Genetic Testing and Genomic Analysis in the Middle East
9.5.2 Brazil: Investments in Research and Innovation Centers and Conferences & Workshops
9.5.3 Rising Prevalence of Hiv, Cancer in Africa
10 Competitive Landscape
10.2 Market Share Analysis
10.2.2 Thermo Fisher Scientific, Inc.
10.2.3 Merck KGaA
10.2.4 Horizon Discovery Group PLC
10.3 Competitive Situation and Trends
10.3.1 Agreements, Collaborations, and Partnerships
10.3.2 Product & Service Launches
10.3.5 Other Strategies
10.4 Strategic Benchmarking
11 Company Profiles
11.1 Thermo Fisher Scientific, Inc.
11.2 Merck KGaA
11.3 Horizon Discovery Group PLC
11.4 Genscript USA Inc.
11.5 Sangamo Biosciences, Inc.
11.6 Integrated DNA Technologies, Inc.
11.7 Lonza Group Ltd.
11.8 New England Biolabs, Inc.
11.9 Origene Technologies, Inc.
11.10 Transposagen Biopharmaceuticals, Inc.
|Single User License||The report will be emailed to you. The report is sent in PDF format.||This is a single user license, allowing one specific user access to the product.|
|Multi User License||The report will be emailed to you. The report is sent in PDF format.||This is a 1-5 user license, allowing up to five users to have access to the product.|
|Corporate License||The report will be emailed to you. The report is sent in PDF format.||This is a 10+ user license, allowing up to 10+ users to have access to the product.|
|Mini Report License||In this you will receive full report except the Company Profile section of this report.||In this you will receive full report except the Company Profile section of this report.|
Toll Free No. : +1-855-984-1862
Call Us. : +91 86 05 657204